Clinical Trials on Group A Streptococcal Infection in Finland

Total 112 results

Tampere University Hospital
Turku University Hospital; University of Turku

Active, not recruiting

Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR) (DICAR)

Invasive Group A Beta-Haemolytic Streptococcal Disease

Finland
Arto Palmu
GlaxoSmithKline

Completed

Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage

Nasopharyngeal Carriage of Streptococcus Pneumoniae

Finland
GlaxoSmithKline

Completed

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (FinIP)

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
Finnish Institute for Health and Welfare
Turku University Hospital; GlaxoSmithKline

Completed

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

Pneumococcal Infections

Finland
GlaxoSmithKline

Completed

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Streptococcus Pneumoniae | Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

Infections, Streptococcal

Belgium, Sweden, Finland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
GlaxoSmithKline

Completed

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Infections, Streptococcal

Finland, France, Poland
Helsinki University Central Hospital

Completed

Targeting of Immune Response After Pneumococcal Vaccination (PncHR)

Pneumococcal Pneumonia

Finland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Infections, Streptococcal

Finland, France, Poland
Finnish Institute for Health and Welfare
Merck Sharp & Dohme LLC; Wyeth-Lederle Vaccines; Pasteur Merieux Connaught

Completed

Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Pneumococcal Infections | Otitis Media

Finland
Helsinki University Central Hospital

Unknown

PCV13 + Hepatitis A Vaccine for Adults (PCV13+HepA)

Measurement of Immune Response to Prevenar13 | Measurement of Immune Response to Hepatitis A

Finland, Sweden
Lars Rombo

Completed

Hepatitis A Vaccine in Patients With Immunomodulating Drugs

Response to Hepatitis A Vaccine

Finland, Sweden
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Pneumococcal Infection

France, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden, Chile, Colombia, Israel
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Pneumococcal Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (PNEU-PLAN)

Pneumococcal Infections

Finland, Malaysia, Poland, Russian Federation, Thailand
Finnish Institute for Health and Welfare

Completed

Evaluation of Pandemic Vaccination Campaign

Influenza Caused by the Novel A(H1N1)v Influenza Virus

Finland
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Pfizer

Completed

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
Pfizer

Completed

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Pneumococcal Disease

Denmark, Belgium, Australia, Poland, Norway, Finland, Netherlands, Italy, Czechia, Estonia, Russian Federation, Slovakia
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Pneumococcal Infections

United States, Australia, Canada, Finland, Germany, Israel, Malaysia, Peru, Taiwan, Thailand
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Pneumococcal Disease

Spain, United States, Canada, Chile, Greece, Germany, Finland, Argentina, Czechia, Hungary, Puerto Rico
University of Helsinki

Completed

Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis

Alcoholic Hepatitis | Alcoholic Cirrhosis

Finland
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

United States
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

HIV Infection | Hepatitis C Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Pfizer

Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

United States
Pfizer

Completed

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Pneumonia, Pneumococcal | Gram-positive Bacterial Infections | Community Acquired Infections

United States, Slovakia, Spain, Taiwan
Merck Sharp & Dohme LLC

Completed

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Hepatitis B

Finland
FibroGen

Terminated

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Liver Fibrosis Due to Chronic Hepatitis B Infection

Hong Kong, Thailand
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
National Institute on Drug Abuse (NIDA)
Rhode Island Hospital

Completed

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

Hepatitis C | Depressive Disorder, Major

United States
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Hepatitis B | Hepatitis B, Chronic | HBV

Hong Kong
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (C_ASCENT)

HIV Infections | Hepatitis C

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

HIV Infections | Hepatitis C

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Pneumonia, Pneumococcal

United States
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico

3

Subscribe